Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...
A machine learning–driven web tool based on 13 standard patient metrics demonstrates strong predictive performance for MASLD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback